Up a level |
Sriuranpong, V. and Altundag, O. and Clingan, P. and Rizvi, N. and Aren Frontera, O. and Sezer, A. and Paydas, S. and Shavdia, M. and Bondarenko, I. and Gladkov, O. and Lee, S. and Li, S. and Snodgrass, P. and Rietschel, P. (2018) EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 50%. Annals of Oncology, Vol.29 (Sup.10). mdy487.039. ISSN 0923-7534 (Print), 1569-8041 (Electronic)